FDA approves new HIV drug Aptivus
pharmafile | June 29, 2005 | News story | Sales and Marketing |Â Â Â
Boehringer Ingelheim's new HIV drug Aptivus has been granted accelerated approval by the FDA.
Aptivus (tipranavir) has been approved for combination treatment with ritonavir in patients with drug-resistant strains of the HIV virus.
The drug is a non-peptidic protease inhibitor (NPPI) and works by inhibiting replication for many strains of HIV that are resistant to a number of existing protease inhibitors.
Dr Daniel Kuritzkes, associate professor of medicine, Harvard Medical School, director of AIDS Research, Brigham and Women Hospital, said: "Aptivus offers an important new treatment option to highly treatment-experienced patients or those with multiple protease inhibitor resistant virus."






